International Medical Research Frontier

Objective: To explore the significance of combined use of bromohexin and cefuroxime sodium in the treatment of pneumonia in children. Methods: the subjects were 90 children with pneumonia who were treated in the hospital from June 2020 to July 2022. They were grouped by digital parity method. 45 patients who received cefuroxime sodium and vitamin C treatment were regarded as the control group, and the other group was regarded as the observation group. The total number of cases was 45. The treatment scheme was bromohexin and cefuroxime. The efficacy and safety differences were compared. Results: the total therapeutic efficiency of the observation group was higher than that of the control group (P < 0.05, ꭓ2 = 6.154); The disappearance time of cough, lung moist rale and fever in the observation group was shorter than that in the control group (P < 0.05) (t = 11.555, 5.818, 8.328); The adverse drug reaction rate of the observation group was lower than that of the control group (P < 0.05) (ꭓ2 = 4.939). Conclusion: the combination of bromohexin and cefuroxime sodium has better overall efficacy and higher safety. It is recommended to popularize it.

pediatric pneumonia; Cefuroxime sodium; Bromohexin; Combination medication; Efficacy and safety